CELEX: 62001CJ0113
Interpretation of Article 28 EC and Article 30 EC
Medicinal products
Withdrawal of parallel import licence in consequence of waiver of the marketing authorisation for the medicinal product of reference

By order of 8 March 2001, received at the Court on 14 March 2001, the Högsta förvaltningsdomstolen (Supreme Administrative
Court, Finland) referred to the Court for a preliminary ruling under Article 234 EC three questions on the interpretation
of Article 28 EC and Article 30 EC.
Those questions were raised in proceedings between Paranova Oy (
Paranova) and the Läkemedelsverket (Finnish Medical Products Agency) concerning the consequences of the withdrawal of a marketing
authorisation on the parallel import into Finland by Paranova of a medicinal product.
Legal framework
Community law
Under Article 28 EC quantitative restrictions on imports and all measures having equivalent effect are prohibited between
Member States.  However, according to Article 30 EC, prohibitions or restrictions on import between Member States which are
justified on the ground,
inter alia
, of the protection of health of humans are authorised so long as they do not constitute a means of arbitrary discrimination
or a disguised restriction on trade between Member States.
According to Article 3 of Directive 65/65/EEC of the Council of 26 January 1965 on the approximation of provisions laid down
by law, regulation or administrative action relating to proprietary medicinal products (OJ, English Special Edition 1965-1966
(I), p. 17), as amended by Council Directive 93/39/EEC of 14 June 1993 (OJ 1993 L 214, p. 22,
Directive 65/65), no medicinal product may be placed on the market in a Member State unless a marketing authorisation has been issued by
the competent authority of that Member State.
Article 4 of Directive 65/65 defines the procedure, documents and information necessary for the issue of a marketing authorisation.
Article 5 of Directive 65/65 states that the marketing authorisation is to be refused if after verification of the particulars
and documents listed in Article 4 it appears that the medicinal product is harmful in the normal conditions of use, or that
its therapeutic efficacy is lacking or is insufficiently substantiated by the applicant, or that its qualitative and quantitative
composition is not as declared.
According to Chapter Va of the Second Council Directive 75/319/EEC of 20 May 1975 on the approximation of provisions laid
down by law, regulation or administrative action relating to proprietary medicinal products (OJ 1975 L 147, p. 13), as amended
by Directive 93/39, the Member States are to set up a pharmacovigilance system which, amongst other things, imposes obligations
on the holder of a marketing authorisation relating to the registration and notification of all adverse reactions to those
medicinal products in humans.  To that end reports must be submitted to the competent authorities at regular intervals and
must be accompanied by a scientific evaluation.
National law
Under Article 101 of the Läkemedelslagen (Finnish Medicinal Products Law No 395/1987), the Läkemedelsverket may prohibit the
importation, manufacture, distribution and sale or any other transfer for consumption of a medicinal product if the conditions
for a marketing authorisation or for a registration or the requirements or obligations that concern the manufacture or the
importation of the medicinal product are no longer fulfilled or if there is reason to believe that such is the case.
Under Regulation 1/1997 of the Läkemedelsverket on the parallel importation of medicinal products, parallel imports are possible
only of medicinal products which are already covered by a marketing authorisation valid in Finland.  Such products must also
be covered by a marketing authorisation valid in the country of supply.  That country must belong to the European Economic
Area.  When dealing with an application for the parallel import of a medicinal product, the Läkemedelsverket has to establish
that the medicinal products are sufficiently similar to be considered to be identical products.
Under the first subparagraph of paragraph 4.3 of that regulation, authorisation for parallel imports (a
parallel import licence) is granted for five years.  However, the validity of that licence depends on that of the marketing authorisations granted
both in Finland and in the country of supply for the directly imported medicinal product and it remains in force only so long
as those authorisations themselves remain valid.  It is for the parallel importer to ensure that each consignment imported
to Finland is covered by a marketing authorisation valid in that Member State and in the country of supply.  If the marketing
authorisation expires in the country of supply, the parallel importer must inform the Läkemedelsverket immediately.
The main proceedings and the questions referred
Suomen Astra Oy (
Astra) held the marketing authorisation in Finland for the medicinal product known as
Losec enterokapslar (Losec enteric capsules, hereinafter the
capsules or
the old version of the product), while Paranova held a parallel import licence for the capsules.  The product is used to treat conditions caused by stomach
acid.
By letter sent to the Läkemedelsverket on 28 September 1998, Astra sought revocation of the marketing authorisation granted
to it for the capsules, explaining that it intended to sell in Finland a new variant of that product called
Losec MUPS enterotabletter (Losec MUPS enteric tablets, hereinafter the
tablets) in place of the capsules.  Subsequently, the Läkemedelsverket withdrew the marketing authorisation held by Astra for the
capsules with effect from 30 September 1998.
The capsules continued to be sold in other Member States, under the marketing authorisations granted in those States.
The two versions of Losec are therapeutic equivalents, that is to say that both versions contain the same dose of the active
ingredient which is absorbed by the body at the same rate and to the same extent when taken orally.
The active ingredient of the capsules contains omeprazole acid.  The tablets contain magnesium salt of omeprazole acid.  The
salt dissolves more easily in water and is more stable.  It is thus easier to manufacture tablets than capsules.
In a letter sent to Paranova on 8 October 1998, the Läkemedelsverket gave notice that it had withdrawn the marketing authorisation
held by Astra for the capsules and that the validity of the licence which Paranova held for the capsules expired on the same
date, that is to say, 30 September 1998.
On 24 November 1998 the Läkemedelsverket gave notice that the parallel import licence held by Paranova for the capsules was
no longer valid, with immediate effect, regardless of any objection by Paranova.  In the grounds for the decision the Läkemedelsverket
pointed out that the parallel import licence did not meet the conditions set out in Regulation 1/1997, since the validity
of the parallel import licence depends on that of the marketing authorisation granted for the medicinal product at issue in
Finland and remains in force only as long as that authorisation is itself valid.
Paranova appealed against that decision before the Högsta förvaltningsdomstolen, claiming that it is incompatible with Article
28 EC and Article 30 EC.  It argued that it became aware of the revocation of the marketing authorisation which Astra held
when its own parallel import licence became invalid.  It thus did not have the time necessary to adapt its stock and sale
contracts concluded before the new situation arose.  For parallel importers, securing a supply which is consistent with consumption
of the medicinal product constitutes one of the most important commercial criteria.
The Läkemedelsverket countered that parallel import licences are granted for five years.  However, their validity is limited
by that of the marketing authorisation of reference in Finland and in the country of origin of the medicinal product imported
as a parallel import.  It is thus for the parallel importer to check that each consignment imported is covered by a marketing
authorisation in both States.  The Läkemedelsverket also contends that the two medicinal products are essentially the same
if they have the same qualitative and quantitative composition in terms of active principles, if they have the same pharmaceutical
form and, where appropriate, if they are
bioequivalent.  However, as the capsules and the tablets have different pharmaceutical forms, they cannot constitute the same medicinal
product.
It is against that background that the Högsta förvaltningsdomstolen decided to stay proceedings and refer the following questions
to the Court of Justice for a preliminary ruling:
1.
Is it compatible with Articles 28 EC and 30 EC for a national agency to decide that a marketing authorisation for a medicinal
product imported as a parallel import automatically comes to an end if the original marketing authorisation for the medicinal
product has been withdrawn at the holder's request for reasons unconnected with the effectiveness or the safety of the medicinal
product and despite the fact that the product has a valid marketing authorisation in the Member State from which the parallel
imports come?
2. If Community law imposes restrictions or conditions on the right of a national agency to decide that a marketing authorisation
for parallel imports comes to an end in the situation referred to in Question 1, what importance should be accorded to the
facts that
(a)
the holder of the original marketing authorisation has obtained a new marketing authorisation for a medicinal product designed
to replace the original medicinal product but that new product is not in the same pharmaceutical form (tablets instead of
capsules) and the active ingredient is not exactly the same (magnesium Omeprazole instead of Omeprazole); on the other hand,
the national agency considers that the medicinal products are bioequivalent and that they have the same therapeutic effect;
(b)
subsequent control of the effectiveness and safety of the medicinal product is possibly made more difficult by the fact that
the marketing authorisation for the original medicinal product has been withdrawn;
(c)
the medicinal product imported as a parallel import has been widely used over many years in Member States and it is improbable
that its continued sale presents a danger to public health?
3. If, in the situation referred to in Question 1, Articles 28 EC and 30 EC allow it to be found that the marketing authorisation
granted for a parallel import has expired, may it be decided that the marketing authorisation for the parallel import expired
immediately the original marketing authorisation was withdrawn, without allowing the parallel importer any time to adapt his
activity?  Do any of the circumstances referred to in Question 2 affect the question whether it may be decided that the marketing
authorisation for a parallel import expires immediately?
The questions referred for a preliminary ruling
As a preliminary point it must be observed that:  ─ the parallel import licence for the capsules (the old version of the medicinal product) was issued by reference to the
marketing authorisation granted by the national authorities for that same medicinal product;  ─ that marketing authorisation was withdrawn at the request of its holder for reasons unconnected with the safety of the
product;  ─ that holder obtained a marketing authorisation for a new variant of that medicinal product, and  ─ the old version of the medicinal product is still marketed legally in other Member States under marketing authorisations
which have not been revoked.
In those circumstances, the question arises as to whether Article 28 EC and Article 30 EC preclude national legislation under
which the withdrawal, at the request of its holder, of the marketing authorisation granted for the old version of a medicinal
product of itself entails the withdrawal of the parallel import licence for that same product.
It must be noted at the outset that the cessation of the validity of a parallel import licence following the withdrawal of
the marketing authorisation of reference constitutes a restriction on the free movement of goods contrary to Article 28 EC
(Case C-172/00
Ferring
[2002] ECR I-6891, paragraph 33).
However, such a restriction may be justified by reasons relating to the protection of public health, in accordance with the
provisions of Article 30 EC (
Ferring
, cited above, paragraph 33).
It is for the national authorities responsible for the operation of the legislation governing the production and marketing
of medicinal products ─ legislation which, as is made clear in the first recital of Directive 65/65, has as its primary objective
the safeguarding of public health ─ to ensure that it is fully complied with.  Nevertheless, the principle of proportionality,
which is the basis of the last sentence of Article 30 EC, requires that the power of the Member States to prohibit imports
of products from other Member States be restricted to what is necessary in order to achieve the aims concerning the protection
of health that are legitimately pursued.  Thus, national legislation or practice cannot benefit from the derogation laid down
in Article 30 EC when the health and life of humans can be protected equally effectively by measures less restrictive of intra-Community
trade (
Ferring
, paragraph 34).
No reason has been put before the Court to justify why the mere fact that a marketing authorisation of reference was withdrawn
at the request of its holder should entail the automatic withdrawal of the parallel import licence issued for the medicinal
product in question (see, to that effect,
Ferring
, paragraph 35).
First, it must be observed that the withdrawal of a marketing authorisation of reference does not mean in itself that the
quality, efficacity and non-toxicity of the old version of the medicinal product is called into question.  In that respect
it must be noted that that version continues to be lawfully marketed in the Member State of exportation under the marketing
authorisation issued in that State (
Ferring
, paragraph 36).
Next, although the competent authorities of the Member State of importation can, and indeed must, adopt the measures necessary
for the purpose of verifying the quality, efficacity and non-toxicity of the old version of the medicinal product, it does
not appear that that objective cannot be attained by other measures having a less restrictive effect on the import of medicinal
products than the automatic cessation of the validity of the parallel import licence in consequence of the withdrawal of the
marketing authorisation of reference (
Ferring
, paragraph 37).
Although adequate monitoring of the old version of the medicinal product remains necessary and may in certain cases mean that
information is requested from the importer, it must be pointed out that pharmacovigilance satisfying the relevant requirements
of Directive 75/319 as amended can ordinarily be guaranteed for medicinal products that are the subject of parallel imports,
such as those in question in the main proceedings, through cooperation with the national authorities of the other Member States
by means of access to the documents and data produced by the manufacturer or other companies in the same group, relating to
the old version in the Member States in which that version is still marketed on the basis of a marketing authorisation still
in force (
Ferring
, paragraph 38).
In that connection, it must be observed that the
Note for Guidance on Procedure for Competent Authorities on the Undertaking of Pharmacovigilance Activities (CPMP/PhVWP/175/95), published in June 1995 by the European Agency for the Evaluation of Medicinal Products, requires, in
its paragraph 3.1.4, that the terminologies used to code medicinal products, adverse reactions to them and diseases should
ensure compatibility of reports between Member States and in particular ensure that reports entered into a database should
be coded according to internationally approved terminologies or with mutually accepted terms allowing connections to be made
with such terminologies.
Finally, it must also be observed that, while it cannot be ruled out that there are reasons relating to the protection of
public health which require a parallel import licence for medicinal products to be linked to a marketing authorisation of
reference, no such reasons are apparent from the observations put before the Court.
If there are no reasons of a general nature which could explain why the withdrawal of the marketing authorisation of reference
should entail that of the parallel import licence, that does not preclude the existence, in specific circumstances, of reasons
relating to the protection of public health which could justify the withdrawal of the parallel import licence.
As the Court has held, such reasons could arise, for example, where there is in fact a risk to public health arising from
the coexistence of two versions of the same medicinal product on the market of the importing Member State (
Ferring
, paragraph 43).
In the light of those considerations the answer to the first question should be that Article 28 EC and Article 30 EC preclude
national legislation under which the withdrawal, at the request of its holder, of the marketing authorisation of reference
of itself entails the withdrawal of the parallel import licence granted for the medicinal product in question.  However, those
provisions do not preclude restrictions on parallel imports of the medicinal product in question if there is in fact a risk
to the health of humans as a result of the continued existence of that medicinal product on the market of the importing Member
State.
In the light of that reply, there is no need to reply to the second question.  Similarly, it is not necessary to consider
the third question in which the referring court essentially seeks to know whether the parallel import licence loses its validity
immediately on withdrawal of the marketing authorisation of reference.
Costs
The costs incurred by the Finnish, Danish, Netherlands and Norwegian Governments and by the Commission, which have submitted
observations to the Court, are not recoverable.  Since these proceedings are, for the parties to the main proceedings, a step
in the action pending before the national court, the decision on costs is a matter for that court.
On those grounds,
THE COURT (Sixth Chamber),
in answer to the questions referred to it by the Högsta förvaltningsdomstolen by order of 8 March 2001, hereby rules:
Puissochet
Gulmann
Macken
Colneric
Cunha Rodrigues
Delivered in open court in Luxembourg on 8 May 2003.
R. Grass
J.-P. Puissochet
Registrar
President of the Sixth Chamber
–
Language of the case: Swedish.